{"id":"https://openalex.org/W997745954","doi":null,"title":"Stimulation of the HER-kinase axis promotes resistance to the Raf-kinase activity of sorafenib, which can be reversed by the addition of MEK inhibitor U0126","display_name":"Stimulation of the HER-kinase axis promotes resistance to the Raf-kinase activity of sorafenib, which can be reversed by the addition of MEK inhibitor U0126","publication_year":2007,"publication_date":"2007-05-01","ids":{"openalex":"https://openalex.org/W997745954","mag":"997745954"},"language":"en","primary_location":{"id":"mag:997745954","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/67/9_Supplement/5412","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009375239","display_name":"Anjali Jain","orcid":"https://orcid.org/0000-0001-5658-367X","observed_orcids":["https://orcid.org/0000-0001-5658-367X"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anjali Jain","raw_affiliation_strings":["Cedars Sinai Medical Center ,  West Hollywood, CA ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars Sinai Medical Center ,  West Hollywood, CA ,","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076447196","display_name":"Michael Hedvat","orcid":"https://orcid.org/0009-0009-1875-6619","observed_orcids":["https://orcid.org/0009-0009-1875-6619"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Hedvat","raw_affiliation_strings":["Cedars Sinai Medical Center ,  West Hollywood, CA ,"],"raw_orcid":"https://orcid.org/0009-0009-1875-6619","affiliations":[{"raw_affiliation_string":"Cedars Sinai Medical Center ,  West Hollywood, CA ,","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061223023","display_name":"Joanna Schmidt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joanna Schmidt","raw_affiliation_strings":["Cedars Sinai Medical Center ,  West Hollywood, CA ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars Sinai Medical Center ,  West Hollywood, CA ,","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012095437","display_name":"David B. Agus","orcid":"https://orcid.org/0000-0002-7499-7822","observed_orcids":["https://orcid.org/0000-0002-7499-7822"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David B. Agus","raw_affiliation_strings":["Cedars Sinai Medical Center ,  West Hollywood, CA ,"],"raw_orcid":"https://orcid.org/0000-0002-7499-7822","affiliations":[{"raw_affiliation_string":"Cedars Sinai Medical Center ,  West Hollywood, CA ,","institution_ids":["https://openalex.org/I1282927834"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1282927834"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0632517,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"67","issue":null,"first_page":"5412","last_page":"5412"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9829000234603882,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9829000234603882,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.009499999694526196,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/raf-kinase-inhibition","display_name":"Raf kinase inhibition","score":0.800000011920929},{"id":"https://openalex.org/keywords/mek1-2-inhibition","display_name":"MEK1/2 inhibition","score":0.8330000042915344},{"id":"https://openalex.org/keywords/u0126","display_name":"U0126","score":0.9789999723434448},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.8429999947547913},{"id":"https://openalex.org/keywords/vegf-receptor-inhibition","display_name":"VEGF receptor inhibition","score":0.734000027179718},{"id":"https://openalex.org/keywords/renal-carcinoma","display_name":"renal carcinoma","score":0.5979999899864197}],"concepts":[{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.9392625093460083},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.738268256187439},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.6233264803886414},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5484424829483032},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.4830670952796936},{"id":"https://openalex.org/C90934575","wikidata":"https://www.wikidata.org/wiki/Q6593810","display_name":"Mitogen-activated protein kinase kinase","level":4,"score":0.47336074709892273},{"id":"https://openalex.org/C59143045","wikidata":"https://www.wikidata.org/wiki/Q15314942","display_name":"Cyclin-dependent kinase 9","level":5,"score":0.472788542509079},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.46602723002433777},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.44678109884262085},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34056079387664795},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3319839835166931},{"id":"https://openalex.org/C97029542","wikidata":"https://www.wikidata.org/wiki/Q281417","display_name":"Protein kinase A","level":3,"score":0.3182748854160309},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2575758993625641},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2121298611164093},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:997745954","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/67/9_Supplement/5412","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.800000011920929,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2139213909","https://openalex.org/W1491779959","https://openalex.org/W1983873711","https://openalex.org/W2008193831","https://openalex.org/W2020391325","https://openalex.org/W4238246462","https://openalex.org/W2102339903","https://openalex.org/W2079478551","https://openalex.org/W3206477885","https://openalex.org/W2140292978"],"abstract_inverted_index":{"AACR":[0],"Annual":[1],"Meeting--":[2],"Apr":[3],"14-18,":[4],"2007;":[5],"Los":[6],"Angeles,":[7],"CA\n\n5412":[8],"\n\nThe":[9],"multi-kinase":[10],"inhibitor,":[11,201],"BAY":[12],"43-9006":[13],"(sorafenib),":[14],"was":[15],"originally":[16],"discovered":[17],"in":[18,54,55,88,104,116,117,136,160,172,193,214],"a":[19,25,96,113,124,199,287],"high":[20,42],"throughput":[21],"kinase":[22,102,119],"screen":[23],"as":[24,112,154],"potent":[26],"inhibitor":[27],"of":[28,91,99,130,157,175,264,281,294],"the":[29,45,52,63,79,86,131,147,168,173,186,225,238,262,265,291],"Raf-MEK-MAPK":[30,148],"pathway":[31,149,267],"(IC50":[32],"for":[33,44,75,240,260,278,290],"B-Raf:":[34],"22\u00b16":[35],"nM;":[36],"Raf-1:":[37],"6\u00b13":[38],"nM).":[39],"Despite":[40],"its":[41,68],"affinity":[43],"Raf-kinases,":[46,92],"sorafenib":[47,60,135,166,218,242,251],"does":[48],"not":[49],"efficiently":[50,171],"block":[51],"Raf-kinases":[53,169],"vivo":[56,89,215],"model":[57],"systems.":[58],"Fortuitously,":[59],"also":[61,182],"inhibits":[62],"VEGF":[64],"receptors,":[65],"which":[66,93],"increased":[67],"clinical":[69],"utility":[70],"and":[71,150,191,283,286],"subsequent":[72],"FDA":[73],"approval":[74],"renal":[76],"carcinoma.":[77],"However,":[78,196],"question":[80],"still":[81],"remains":[82],"with":[83,198],"respect":[84],"to":[85,227,229],"efficient":[87,279,292],"targeting":[90],"lie":[94],"at":[95],"critical":[97],"junction":[98],"several":[100,137,161],"interacting":[101],"networks":[103],"cancer":[105,138],"cells.\n\nUtilizing":[106],"sorafenib\u2019s":[107],"effect":[108],"on":[109,208],"Raf-kinase":[110,132,296],"activity":[111,133],"molecular":[114,288],"readout":[115],"vitro":[118],"assays,":[120],"we":[121],"demonstrate":[122],"that":[123,213],"ligand-stimulated":[125],"HER-kinase":[126,143,176,204],"axis":[127,144],"compromises":[128],"inhibition":[129,207],"by":[134,217,250,269],"cell":[139],"lines.":[140],"An":[141],"active":[142,235],"works":[145],"via":[146],"is":[151],"commonly":[152],"recognized":[153],"an":[155],"initiator":[156],"cellular":[158],"proliferation":[159],"solid":[162],"tumors.":[163],"In":[164],"contrast,":[165],"blocked":[167],"more":[170],"absence":[174],"specific":[177],"stimulation.":[178],"These":[179,210],"differences":[180],"are":[181,237,253,258],"observed":[183],"when":[184],"evaluating":[185],"downstream":[187],"effectors,":[188],"i.e.,":[189],"phospho-MEK":[190],"phospho-MAPK":[192],"western":[194],"blots.":[195],"combination":[197,280],"MEK1/2-specific":[200,246],"U0126,":[202],"boosts":[203],"stimulated,":[205],"sorafenib-specific":[206],"phospho-MAPK.":[209],"results":[211,272],"indicate":[212],"Raf-inhibition":[216],"may":[219],"exclude":[220],"MEK1/2":[221],"inhibition,":[222],"thus":[223],"allowing":[224],"cells":[226],"continue":[228],"proliferate.":[230],"To":[231],"conclusively":[232],"address":[233],"if":[234],"MEK-kinases":[236],"reason":[239],"inefficient":[241],"activity,":[243],"experiments":[244],"combining":[245],"siRNA":[247],"knockdown":[248],"followed":[249],"treatment":[252],"being":[254],"performed.":[255],"Further":[256],"studies":[257],"warranted":[259],"delineating":[261],"components":[263],"Raf":[266,282],"targeted":[268],"sorafenib.":[270],"Nonetheless,":[271],"from":[273],"our":[274],"study":[275],"provide":[276],"justification":[277],"MEK":[284],"inhibitors":[285],"framework":[289],"design":[293],"future":[295],"inhibitors.":[297]},"counts_by_year":[],"updated_date":"2025-10-10T17:16:08.811792","created_date":"2016-06-24T00:00:00"}